The Conversation (0)
Theratechnologies Announces Financial Results for Fiscal Year 2017
Feb. 07, 2018 09:05AM PST
Pharmaceutical InvestingTheratechnologies (TSX:TH) announced its financial results for the year ended November 30, 2017. As quoted in the press release: Selling and market development expenses amounted to $7,985,000 for the three months ended November 30, 2017, compared to $3,762,000 for the comparable period of Fiscal 2016. The higher expenses in 2017 were largely due to the planned increase …
Theratechnologies (TSX:TH) announced its financial results for the year ended November 30, 2017.
As quoted in the press release:
Selling and market development expenses amounted to $7,985,000 for the three months ended November 30, 2017, compared to $3,762,000 for the comparable period of Fiscal 2016. The higher expenses in 2017 were largely due to the planned increase in selling and market development activities as described above. Principally among these were: the expansion of our U.S. sales team in order to prepare for the potential launch of ibalizumab and to cover additional territories, added staff in our medical science liaison, managed markets and call-center groups, preparatory work on branded and unbranded ibalizumab campaigns, the development of a U.S. pricing strategy for ibalizumab and marketing plans for ibalizumab in Europe.
